/
Oncology
Non-Small Cell Lung Cancer Stage III
5
Pipeline Programs↗
5
Active Trials↗
4
Companies Involved↗
Non-small Cell Lung Cancer Stage III is an early-stage landscape with 5 programs across 4 companies. 2 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Approved
No programs
Analysis
Modality Breakdown
60%
Monoclonal antibody
3 of 5 classified programs — the dominant modality here.
Monoclonal antibody leads; the ring shows all 5 classified programs, each share of the total. Modality classified for 100% of 5 pipeline programs.
Analysis
Trial Status
6
clinical trials
Recruiting3 · 50%
Completed1 · 17%
Not yet recruiting1 · 17%
Active, not recruiting1 · 17%
Clinical Trials
Trial Activity
6 trials
ChemoRadiOtherapy With Surgery Followed by Consolidation Durvalumab for Initially Unresectable Stage III NSCLC (CROWD): a Phase IV Feasibility Trial
Recruiting·—·Approved·NCT06908070·38 enrolled
ctDNA-guIDEd consolidATION Immunotherapy After Chemoradiotherapy in Patients With Stage III Non-small Cell Lung Cancer
Not yet recruiting·IIntergroupe Francophone de Cancerologie Thoracique·Phase 2·NCT07759492·177 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)